中医药治疗慢性乙型肝炎肝纤维化的临床研究

Clinical research on treating hepatic fibrosis from chronic hepatitis B with TCM treatment

目的:观察中医药治疗慢性乙型肝炎肝纤维化的临床疗效。方法:76例乙型肝炎肝纤维化患者随机分为观察和对照组各38例,对照组例采用阿德福韦酯联合硫普罗宁治疗,观察组例在对照组的基础上采用中医药治疗;均连续治疗6个月后观察两组治疗前后肝纤维化及肝脾B超影像变化。结果:两组患者治疗后肝纤维化程度的HA、LN、IV-C均有明显下降,治疗前后比较差异均有统计学意义(aP<0.05);治疗后两组组间比较,观察组的HA、LN、IV-C均低于对照组,差异均有统计学意义(bP<0.05);治疗后两组患者的门静脉内径、脾静脉内径和脾脏厚度均有明显下降,治疗前后比较差异均有统计学意义(cP<0.05);且治疗后观察组的门静脉内径、脾静脉内径和脾脏厚度均低于对照组,差异均有统计学意义(dP<0.05)。结论:中医药治疗慢性乙型肝炎肝纤维化疗效确切,值得进一步深入研究。

Objective： To investigate the clinical effect of TCM treatment on hepatic fibrosis from chronic hepatitis B. Methods： 76 patients were randomly divided into two groups, 38 in each group. The control group was given Adefovir combined with Tiopronin, while the treated group was given TCM treatment more. Results： HA, LN and IV-C in both groups decreased after 6 month treatment, with significant differences （ap〈0.05）. HA, LN and IV-C in the treated group were significantly lower than those in the control group （bP〈0.05）. The inner diameters of portal vein and splenic vein and the thickness of spleen decreased significantly （cP〈0.05） and those in the treated group were significantly lower than those in the control group （aP〈0.05）. Conclusion： TCM treatment was significantly effective on hepatic fibrosis from chronic hepatitis B, worthy of further research.